Connect with us
  • tg

Stock Markets

Opaleye Management Inc. sells shares worth nearly $18k in Protara Therapeutics

letizo News

Published

on

Opaleye Management Inc., a notable investment management firm, has recently sold shares in Protara Therapeutics, Inc. (NASDAQ:TARA), a company specializing in biological products. The transactions, which took place on July 1, 2024, involved the sale of a total of 8,288 shares of common stock at an average price of $2.1233, amounting to nearly $18,000.

The sales were carried out in multiple transactions with prices ranging from $2.1021 to $2.1611. This information comes from a recent Form 4 filing with the Securities and Exchange Commission, which details the trading activities of the company’s insiders.

The bulk of the shares, specifically 5,788 shares, were sold by Opaleye, L.P., a fund managed by Opaleye Management Inc., leaving them with a remaining interest of 2,213,474 shares. Additionally, a separately managed account under Opaleye’s portfolio management offloaded 2,500 shares, resulting in an ownership of 87,500 shares post-transaction.

The sales reflect transactions by an entity that is considered a ten percent owner of Protara Therapeutics, thus making these disclosures significant for investors monitoring insider activity. Opaleye Management, through its control of Opaleye, L.P. and the managed account, may be deemed to beneficially own the shares held by both entities.

Investors and the market at large often keep a close eye on insider trading patterns as they can provide insights into a company’s internal perspective and future prospects. The recent sales by Opaleye Management Inc. are now part of the public record and provide additional data points for those analyzing Protara Therapeutics’ stock performance and ownership structure.

In other recent news, Protara Therapeutics has been making significant strides in its various clinical trials. The company recently announced positive three-month data from its ongoing clinical studies of TARA-002 in patients with high-risk non-muscle invasive bladder cancer (NMIBC), which has prompted Oppenheimer to increase the stock price target to $30 from the previous $26. TD Cowen also maintained a positive outlook on Protara Therapeutics, reiterating a Buy rating and a $50.00 price target for the company’s stock, citing the encouraging results from the trials.

Protara Therapeutics also recently completed a $45 million private investment in public equity (PIPE) deal, attracting several prominent life science funds. This financial boost is expected to extend the company’s cash runway into 2026, providing a stable financial platform for continued development.

The company is also planning to initiate a registrational trial for IV Choline Chloride, targeting parenteral nutrition (PN) patients, in the first half of 2025. This comes after discussions with the U.S. Food and Drug Administration (FDA), expanding the drug’s potential use to a broader patient population.

Furthermore, Protara Therapeutics has announced a private placement financing deal expected to generate approximately $45 million in gross proceeds. The proceeds from this private placement, combined with existing cash reserves, are anticipated to fund operations into 2026.

These are the recent developments that have been reported about Protara Therapeutics.

InvestingPro Insights

As Protara Therapeutics, Inc. (NASDAQ:TARA) experiences insider trading activity, investors seeking a deeper understanding of the company’s financial health can turn to real-time data from InvestingPro. With a market capitalization of $43.03 million USD and a concerning price-to-earnings (P/E) ratio of -0.55, Protara’s financial landscape presents a complex picture. Further analysis shows that the stock’s price is currently at 40.08% of its 52-week high, and it closed at $2.03 USD in the previous session.

InvestingPro Tips for Protara Therapeutics highlight several critical factors that investors may want to consider. Notably, the company holds more cash than debt on its balance sheet, which is a positive sign for financial stability. Additionally, two analysts have revised their earnings upwards for the upcoming period, potentially indicating a more optimistic outlook for the company’s financial performance. However, it’s important to note that Protara is quickly burning through cash and suffers from weak gross profit margins, which could raise concerns about its long-term sustainability.

For investors interested in a comprehensive analysis, there are 13 additional InvestingPro Tips available for Protara Therapeutics, which can be accessed by visiting https://www.investing.com/pro/TARA. To deepen your investment research, consider utilizing the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, offering you an even greater array of tools and insights.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Stock Markets

Palantir, Anduril join forces with tech groups to bid for Pentagon contracts, FT reports

letizo News

Published

on

(Reuters) – Data analytics firm Palantir Technologies (NASDAQ:) and defense tech company Anduril Industries are in talks with about a dozen competitors to form a consortium that will jointly bid for U.S. government work, the Financial Times reported on Sunday.

The consortium, which could announce agreements with other tech groups as early as January, is expected to include SpaceX, OpenAI, autonomous shipbuilder Saronic and artificial intelligence data group Scale AI, the newspaper said, citing several people with knowledge of the matter.

“We are working together to provide a new generation of defence contractors,” a person involved in developing the group told the newspaper.

The consortium will bring together the heft of some of Silicon Valley’s most valuable companies and will leverage their products to provide a more efficient way of supplying the U.S. government with cutting-edge defence and weapons capabilities, the newspaper added.

Palantir, Anduril, OpenAI, Scale AI and Saronic did not immediately respond to a Reuters request for comment. SpaceX could not be immediately reached for a comment.

Reuters reported earlier this month that President-elect Donald Trump’s planned U.S. government efficiency drive involving Elon Musk could lead to more joint projects between big defense contractors and smaller tech firms in areas such as artificial intelligence, drones and uncrewed submarines.

Musk, who was named as a co-leader of a government efficiency initiative in the incoming government, has indicated that Pentagon spending and priorities will be a target of the efficiency push, spreading anxiety at defense heavyweights such as Boeing (NYSE:) , Northrop Grumman (NYSE:) , Lockheed Martin (NYSE:) and General Dynamics (NYSE:) .

Musk and many small defense tech firms have been aligned in criticizing legacy defense programs like Lockheed Martin’s F-35 fighter jet while calling for mass production of cheaper AI-powered drones, missiles and submarines.

Such views have given major defense contractors more incentive to partner with emerging defense technology players in these areas.

Continue Reading

Stock Markets

Weakened Iran could pursue nuclear weapon, White House’s Sullivan says

letizo News

Published

on

By Simon Lewis (JO:)

(Reuters) -The Biden administration is concerned that a weakened Iran could build a nuclear weapon, White House National Security Adviser Jake Sullivan said on Sunday, adding that he was briefing President-elect Donald Trump’s team on the risk.

Iran has suffered setbacks to its regional influence after Israel’s assaults on its allies, Palestinian Hamas and Lebanon’s Hezbollah, followed by the fall of Iran-aligned Syrian President Bashar al-Assad.

Israeli strikes on Iranian facilities, including missile factories and air defenses, have reduced Tehran’s conventional military capabilities, Sullivan told CNN.

“It’s no wonder there are voices (in Iran) saying, ‘Hey, maybe we need to go for a nuclear weapon right now … Maybe we have to revisit our nuclear doctrine’,” Sullivan said.

Iran says its nuclear program is peaceful, but it has expanded uranium enrichment since Trump, in his 2017-2021 presidential term, pulled out of a deal between Tehran and world powers that put restrictions on Iran’s nuclear activity in exchange for sanctions relief.

Sullivan said that there was a risk that Iran might abandon its promise not to build nuclear weapons.

“It’s a risk we are trying to be vigilant about now. It’s a risk that I’m personally briefing the incoming team on,” Sullivan said, adding that he had also consulted with U.S. ally Israel.

Trump, who takes office on Jan. 20, could return to his hardline Iran policy by stepping up sanctions on Iran’s oil industry.

© Reuters. FILE PHOTO: Iranian flag flies in front of the UN office building, housing IAEA headquarters, in Vienna, Austria, May 24, 2021. REUTERS/Lisi Niesner/File Photo

Sullivan said Trump would have an opportunity to pursue diplomacy with Tehran, given Iran’s “weakened state.”

“Maybe he can come around this time, with the situation Iran finds itself in, and actually deliver a nuclear deal that curbs Iran’s nuclear ambitions for the long term,” he said.

Continue Reading

Stock Markets

Ukraine says Russian general deliberately targeted Reuters staff in August missile strike

letizo News

Published

on

(Reuters) -Ukraine’s security service has named a Russian general it suspects of ordering a missile strike on a hotel in eastern Ukraine in August and said he acted “with the motive of deliberately killing employees of” Reuters.

The Security Service of Ukraine (SBU) said in a statement on Friday that Colonel General Alexei Kim, a deputy chief of Russia’s General Staff, approved the strike that killed Reuters safety adviser Ryan Evans and wounded two of the agency’s journalists on Aug. 24.

In a statement posted on Telegram messenger the SBU said it was notifying Kim in absentia that he was an official suspect in its investigation into the strike on the Sapphire Hotel in Kramatorsk, a step in Ukrainian criminal proceedings that can later lead to charges.

In a separate, 15-page notice of suspicion, in which the SBU set out findings from its investigation, the agency said that the decision to fire the missile was made “with the motive of deliberately killing employees of the international news agency Reuters who were engaged in journalistic activities in Ukraine”.

The document, which was published on the website of the General Prosecutor’s Office on Friday, said that Kim had received intelligence that Reuters staff were staying in Kramatorsk. It added that Kim would have been “fully aware that the individuals were civilians and not participating in the armed conflict”.

The Russian defence ministry did not respond to a request for comment on the SBU’s findings and has not replied to previous questions about the attack. The Kremlin also did not respond to a request for comment. Kim did not reply to messages sent by Reuters to his mobile telephone seeking comment about the SBU’s statement and whether the strike deliberately targeted Reuters staff.

The SBU did not provide evidence to support its claims, nor say why Russia targeted Reuters. In response to questions from the news agency, the security agency declined to provide further details, saying its criminal investigation was still under way and it was therefore not able to disclose such information.

Reuters has not independently confirmed any of the SBU’s claims.

Reuters said on Friday: “We note the news today from the Ukrainian security services regarding the missile attack on August 24, 2024, on the Sapphire Hotel in Kramatorsk, a civilian target more than 20 km from Russian-occupied territory.”

“The strike had devastating consequences, killing our safety adviser, Ryan Evans, and injuring members of our editorial team. We continue to seek more information about the attack. It is critically important for journalists to be able to report freely and safely,” the statement said.

Reuters declined to comment further on the allegation that its staff were deliberately targeted.

The SBU statement said Kim had been named a suspect under two articles of the Ukrainian criminal code: waging an aggressive war and violating the laws and customs of war.

“It was Kim who signed the directive and gave the combat order to fire on the hotel, where only civilians were staying,” it said.

Evans, a 38-year-old former British soldier who had worked as a safety adviser for Reuters since 2022, was killed instantly in the strike.

The SBU statement gave some details about how the strike had occurred, according to its investigation.

“To carry out the attack, the Russian colonel general involved one of his subordinate missile forces units,” the Ukrainian agency said, adding that the strike was carried out with an Iskander-M ballistic missile.

The SBU did not identify the specific unit.

© Reuters. FILE PHOTO: Reuters safety advisor Ryan Evans holds a cat during a news assignment, as Russia's attack on Ukraine continues, during intense shelling in Kramatorsk, Ukraine, December 26, 2022. REUTERS/Clodagh Kilcoyne/File Photo

Ivan Lyubysh-Kirdey, a videographer for the news agency who was in a room across the corridor, was seriously wounded. Kyiv-based text correspondent Dan Peleschuk was also injured.

The remaining three members of the Reuters team escaped with minor cuts and scratches.

Continue Reading

Trending

©2021-2024 Letizo All Rights Reserved